Pfizer Inc.

Pfizer Inc.

0Q1N · LSE

28.80USD-0.15 (-0.52%)

Price History

Full chart

Market Stats

Previous Close28.95
Open28.85
Day Range28.63 – 29.16
52-Week Range20.75 – 29.90
Volume77.86K
Market Cap162.27B
P/E (TTM)0.21
Forward P/E9.65
EPS1.38
Dividend Yield7.34%
Beta0.30
50-Day Avg26.27
200-Day Avg25.64

About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company Details

  • CEODr. Albert Bourla D.V.M., Ph.D.
  • Employees75.00K
  • Headquarters66 Hudson Boulevard East, New York, NY, United States, 10001-2192, UK
  • Websitehttps://www.pfizer.com

Leadership

  • Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · b. 1962
  • Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · b. 1964
  • Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · b. 1966
  • Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · b. 1976
  • Ms. Cecile GueganInterim CFO & Executive VP · b. 1971
  • Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · b. 1969
  • Mr. Dennis P. HancockExecutive VP & Chief Information Officer
  • Ms. Francesca M. DeMartinoChief Investor Relations Officer
  • Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · b. 1975
  • Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue52.82B52.55B40.83B41.17B41.91B81.29B100.33B59.55B63.63B62.58B
Growth (%)--0.53%-22.31%+0.85%+1.79%+93.97%+23.43%-40.64%+6.84%-1.65%
Cost of Revenue11.93B10.84B8.87B8.04B8.57B30.82B34.34B24.95B17.85B16.07B
Gross Profit40.90B41.71B31.95B33.13B33.33B50.47B65.99B34.60B45.78B46.51B
Gross Margin77.43%79.37%78.27%80.46%79.54%62.08%65.77%58.10%71.94%74.33%
Operating Expense31.89B28.72B27.89B20.80B25.06B26.76B28.71B30.18B30.84B29.11B
Operating Income9.00B12.99B4.06B12.33B8.27B23.70B37.27B4.42B14.94B17.41B
Operating Margin17.05%24.72%9.95%29.95%19.74%29.16%37.15%7.42%23.48%27.82%
EBITDA------41.03B9.56B18.13B16.78B
EBITDA Margin------40.90%16.05%28.49%26.82%
Net Income7.21B21.31B11.15B16.27B9.62B21.98B31.37B2.12B8.03B7.77B
Net Income Margin13.66%40.55%27.32%39.52%22.94%27.04%31.27%3.56%12.62%12.42%
R&D----9.39B10.36B11.43B10.68B10.82B10.44B
R&D as % of Total Revenue----22.41%12.74%11.39%17.93%17.01%16.68%
Interest Expense00001.45B1.29B1.24B2.21B3.09B2.67B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%3.46%1.59%1.23%3.71%4.86%4.27%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets171.62B171.80B159.42B167.59B154.23B181.48B197.21B226.50B213.40B208.16B
Total Liabilities112.07B100.49B96.02B104.45B90.99B104.01B101.29B137.21B124.90B121.39B
Total Equity59.54B71.31B63.41B63.14B63.24B77.20B95.66B89.01B88.20B86.48B
Cash2.60B1.34B1.14B1.12B1.78B1.94B416.00M2.85B1.04B1.14B
Total Debt31.40B33.54B32.91B35.95B37.13B-----
Net Debt----36.49B35.05B34.44B67.99B62.61B62.82B

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow16.19B16.80B15.83B12.59B14.40B32.58B29.27B8.70B12.74B11.70B
Investing Cash Flow-7.79B-4.74B4.53B-3.94B-4.27B-22.55B-15.78B---
Financing Cash Flow-9.23B-13.35B-20.44B-8.48B-9.65B-9.82B-14.83B26.07B-17.14B-10.30B
Capital Expenditure2.00B2.22B1.98B2.05B2.23B2.71B3.24B3.91B2.91B2.63B
Free Cash Flow----12.18B29.87B26.03B4.79B9.84B9.07B
Dividends Paid7.32B7.66B7.98B8.04B8.44B8.73B8.98B9.25B9.51B9.77B
FCF to OCF----84.54%91.68%88.94%55.09%77.17%77.54%
Dividend Paid to FCF----69.31%29.22%34.51%192.93%96.72%107.67%

Earnings

Report DateJun 30, 2001Sep 30, 2001Dec 31, 2001Mar 31, 2002Jun 30, 2002Sep 30, 2002Dec 31, 2002Mar 31, 2003Jun 30, 2003Sep 30, 2003Dec 31, 2003Mar 31, 2004Jun 30, 2004Sep 30, 2004Dec 31, 2004Mar 31, 2005Jun 30, 2005Sep 30, 2005Dec 31, 2005Mar 31, 2006Jun 30, 2006Sep 30, 2006Dec 31, 2006Mar 31, 2007Jun 30, 2007Sep 30, 2007Dec 31, 2007Mar 31, 2008Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020May 4, 2021Jul 28, 2021Nov 2, 2021Feb 8, 2022May 3, 2022Jul 28, 2022Nov 1, 2022Jan 31, 2023May 2, 2023Aug 1, 2023Oct 31, 2023Mar 12, 2024May 1, 2024Jul 30, 2024Oct 29, 2024Feb 4, 2025Apr 29, 2025Aug 5, 2025Nov 4, 2025Feb 3, 2026May 5, 2026Aug 4, 2026Nov 3, 2026
EPS Estimate-----------------------------------------------------------0.560.630.620.50---------------------------------0.570.640.570.720.680.76
EPS Actual0.290.330.310.370.310.380.460.76-0.480.290.080.300.370.440.380.040.470.220.370.560.330.461.320.480.180.110.400.410.410.340.040.400.330.430.100.250.310.110.360.280.330.480.190.240.430.430.850.381.980.390.390.360.450.420.190.380.420.34-0.030.670.640.610.470.510.510.472.020.590.650.69-0.070.680.891.36-0.060.610.610.390.100.860.981.420.591.371.731.510.870.970.41-0.42-0.600.550.010.780.070.520.510.62-0.290.47-0.04-
Surprise-----------------------------------------------------------19.64%1.59%-1.61%-6.00%----------------------------------10.53%-3.17%-150.84%-34.88%-106.40%-
Timing----------------------------------------------------------------------------------Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap162.27B
Enterprise Value212.11B
Trailing P/E0.21
Forward P/E9.65
PEG Ratio12.87
Price / Sales2.55
Price / Book1.88
EPS1.38
Book Value14.95
Revenue (TTM)63.70B
Gross Profit (TTM)47.59B
EBITDA25.38B
Profit Margin6.80%
Operating Margin27.88%
Return on Equity5.01%
Return on Assets5.78%
Shares Outstanding5.69B
Shares Float5.69B
Beta0.30
Dividend Yield7.34%
Dividend Rate1.72
Payout Ratio2.28%

Dividends

20264×
0.43Nov 6, 20260.43Jul 23, 20260.43May 7, 20260.43Jan 22, 2026
20254×
0.43Nov 6, 20250.43Jul 24, 20250.43May 8, 20250.43Jan 23, 2025
20244×
0.42Nov 8, 20240.42Jul 26, 20240.42May 9, 20240.42Jan 25, 2024
20234×
0.41Nov 9, 20230.41Jul 27, 20230.41May 11, 20230.41Jan 26, 2023
20224×
0.40Nov 3, 20220.40Jul 28, 20220.40May 12, 20220.40Jan 27, 2022
20214×
0.39Nov 4, 20210.39Jul 29, 20210.39May 6, 20210.39Jan 28, 2021